Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 27, 2015 11:40 PM ET

Biotechnology

Company Overview of Genentech, Inc.

Company Overview

Genentech, Inc., a biotechnology company, engages in the research, development, manufacture, and marketing of biotechnology products for treating patients with serious or life-threatening diseases in the United States. It offers molecular entities and medicines in the areas of oncology, immunology, neuroscience, metabolism, and infectious diseases. The company also offers hematology medicines that include antibody-drug conjugates, small molecule antagonists, and small molecule BCL-2 inhibitors. Genentech, Inc. has a strategic alliance with Array biopharma. The company was founded in 1976 and is headquartered in South San Francisco, California. Genentech, Inc. operates as a subsidiary of Roch...

1 DNA Way Mailstop 258A

South San Francisco, CA 94080-4990

United States

Founded in 1976

11,186 Employees

Phone:

650-225-1000

Fax:

650-225-4630

Key Executives for Genentech, Inc.

Chief Executive Officer, Head of North American Commercial Operations and Director
Age: 54
Co-Founder and Member of Scientific Resource Board
Age: 78
Senior Vice President and General Counsel
Chief Compliance Officer, Head of Legal Affairs for North America, Senior Vice President and Secretary
Vice President of Human Resources and Regional Human Resources Head of North America
Compensation as of Fiscal Year 2015.

Genentech, Inc. Key Developments

Genentech Announces Positive Results from Two Pivotal Studies Evaluating the Investigational Medicine Ocrelizumab

Genentech announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif®), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease. The studies (called OPERA I and OPERA II) met their primary and major secondary endpoints. Treatment with ocrelizumab significantly reduced the annualized relapse rate (ARR) over a two-year period compared with interferon beta-1a, the primary endpoint in both studies. Ocrelizumab also significantly reduced the progression of clinical disability compared with interferon beta-1a, as measured by the Expanded Disability Status Scale (EDSS). Additionally, treatment with ocrelizumab led to a significant reduction in the number of lesions in the brain (areas of disease activity) compared with interferon beta-1a, as measured by MRI. Overall, the incidence of adverse events associated with ocrelizumab was similar to interferon beta-1a in both studies; the most common adverse events were mild-to-moderate infusion-related reactions. The incidence of serious adverse events associated with ocrelizumab, including serious infections, was also similar to interferon beta-1a.

Almac Discovery Ltd. and Genentech Inc. Sign Research and Licensing Agreement

Almac Discovery Ltd. announced that it had signed a research and licensing agreement with Genentech Inc. Almac and Genentech will work together to discover and develop small molecule inhibitors of a ubiquitin specific protease (USP) target. The company will be paid USD 14.5 million (EUR 12.9 million) upfront and stands to receive up to USD 349 million on top of that from milestone payments and escalating tiered royalties tied to commercial sales results. The joint research programme will run for two years, using as its starting point the small molecule inhibitors developed by Almac. Genentech's responsibilities will involve all pre-clinical and clinical development and commercialization of products created by the partners under this collaboration.

Genentech, Inc. Presents at BIO International Convention 2015, Jun-16-2015 10:45 AM

Genentech, Inc. Presents at BIO International Convention 2015, Jun-16-2015 10:45 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Mark Rowen, Associate Director, Business Development.

Similar Private Companies By Industry

Company Name Region
Bio-Defense Research Group, Inc. United States
AndroBioSys, Inc. United States
IDM Pharma, Inc. United States
Georgia Tissue Bank, Inc. United States
XL Techgroup, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genentech, Inc., please visit www.gene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.